-
公开(公告)号:US20190194260A1
公开(公告)日:2019-06-27
申请号:US16083652
申请日:2017-03-11
申请人: The United States of America, as represented by the Secretary, Dept. of Health and Human Services , The Johns Hopkins University
发明人: Stephen S. Whitehead , Sara E. Woodson , Anna P. Durbin , Alexander G. Pletnev , Konstantin A. Tsetsarkin
IPC分类号: C07K14/005 , A61K39/12
CPC分类号: C07K14/005 , A61K39/12 , A61K2039/5254 , A61K2039/5256 , C12N2770/24122 , C12N2770/24134 , C12N2770/24144 , C12N2770/24162 , Y02A50/386 , Y02A50/388 , Y02A50/39 , Y02A50/392 , Y02A50/394 , Y02A50/396
摘要: The present disclosure relates to attenuated Zika viruses and vaccines, attenuated chimeric Zika viruses and vaccines, and to multivalent immunogenic compositions comprising Zika vaccines and vaccines to other flaviviruses. The chimeric Zika viruses includes a first nucleotide sequence encoding at least one structural protein from a Zika virus (ZIKV), a second nucleotide sequence encoding at least one nonstructural protein from a first flavivirus, and a third nucleotide sequence of a 3′ untranslated region from a second flavivirus. The multivalent immunogenic compositions comprise an attenuated ZIKV vaccine or an attenuated chimeric ZIKV vaccine (or their combination) together with one or more of a first attenuated virus that is immunogenic against dengue serotype 1, a second attenuated virus that is immunogenic against dengue serotype 2, a third attenuated virus that is immunogenic against dengue serotype 3, and a fourth attenuated virus that is immunogenic against dengue serotype 4. The present disclosure further relates to methods of inducing immune responses, as well as preventing or treating ZIKV infections, and in certain embodiments, the combined prevention or treatment of ZIKV and another flavivirus, e.g., dengue virus.
-
公开(公告)号:US20190185520A1
公开(公告)日:2019-06-20
申请号:US16319363
申请日:2017-07-24
发明人: ROY CURTISS, III
IPC分类号: C07K14/005 , A61K39/12
CPC分类号: C07K14/005 , A61K39/12 , A61K2039/522 , A61K2039/523 , A61K2039/53 , C12N1/20 , C12N1/36 , C12N2770/24122 , C12N2770/24134 , C12N2770/24162 , C12N2770/24171 , C12R1/42 , Y02A50/386 , Y02A50/392 , Y02A50/484
摘要: The subject application provides a genetically modified recombinant facultative intracellular invasive bacterial pathogen (RFIIBP) or a recombinant attenuated Salmonella vaccine (RASV) strains encoding Zika virus (ZIKV) antigens. These strains exhibit high immunogenicity, complete safety, and attenuation, and are unable to persist or be shed in an infective or viable form. These RFIIBPs and RASVs also exhibit regulated delayed attenuation in vivo, regulated delayed in vivo synthesis of protective ZIKV antigens. Methods of inducing mucosal, systemic and cellular immunities in hosts are also provided and antibodies produced using the disclosed RFIIBPs and RASVs can comprise neutralizing antibodies against ZIKV that do not crossreact with Dengue virus (DENV).
-
公开(公告)号:US20190002837A1
公开(公告)日:2019-01-03
申请号:US15508695
申请日:2015-09-08
发明人: Eckard Wimmer , Steffen Mueller , Bruce Futcher , Sam Shen , Charles Stauft , Charles Ward
CPC分类号: C12N7/00 , A61K39/12 , A61K2039/5254 , C12N7/04 , C12N2760/12221 , C12N2760/12233 , C12N2760/12234 , C12N2760/12262 , C12N2760/20062 , C12N2770/24121 , C12N2770/24122 , C12N2770/24134 , C12N2770/24162 , C12N2800/22 , Y02A50/386
摘要: This invention provides an attenuated virus comprising a modified viral genome engineered to containing multiple nucleotide substitutions that reduce the codon pair bias of a virus protein encoding sequence relative to a first host while the codon pair bias relative to a second host is not substantially reduced. In another embodiment, the invention provides an attenuated virus comprising modified viral genome engineered to containing multiple nucleotide substitutions that reduce the codon pair bias of a virus protein-encoding sequence relative to a first host and a second host. The attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the attenuated virus.
-
公开(公告)号:US20180369358A1
公开(公告)日:2018-12-27
申请号:US16025624
申请日:2018-07-02
申请人: The United States of America, as represented by the Secretary, Dept. of Health and Human Services , The Government of the United States, as Represented by The Secretary of the Army
发明人: Alexander G. Pletnev , Joseph R. Putnak , Robert M. Chanock , Brian R. Murphy , Stephen S. Whitehead , Joseph E. Blaney
IPC分类号: A61K39/12 , C12Q1/6888 , C12N7/00 , C07K14/005 , C12N15/86 , A61K39/00
CPC分类号: A61K39/12 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2770/24122 , C12N2770/24134 , C12N2770/24143 , C12N2770/24162 , C12Q1/6888 , Y02A50/386 , Y02A50/394
摘要: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.
-
公开(公告)号:US10081795B2
公开(公告)日:2018-09-25
申请号:US13069905
申请日:2011-03-23
IPC分类号: A61K39/12 , A61K39/00 , C07K14/005 , C12N7/00 , C07K16/10
CPC分类号: C12N7/00 , A61K39/12 , C12N2770/24134 , C12N2770/24161 , C12N2770/24162 , Y02A50/386 , Y02A50/388 , Y02A50/39 , Y02A50/394 , Y02A50/396
摘要: Methods and compositions concerning mutant flaviviruses with host range mutations. In some embodiments the invention concerns nucleotide sequences that encode mutant flavivirus proteins. Viruses comprising these sequences that display reduced replication in mammalian cells are provided. In further aspects of the invention, flavivirus vaccine compositions are provided. In another embodiment the invention provides methods for vaccination against flavivirus infection.
-
6.
公开(公告)号:US20180008693A1
公开(公告)日:2018-01-11
申请号:US15650482
申请日:2017-07-14
申请人: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
IPC分类号: A61K39/12 , C12Q1/70 , C12N7/00 , A61K39/295 , A61K39/00
CPC分类号: A61K39/12 , A61K39/295 , A61K2039/5252 , A61K2039/5254 , A61K2039/5256 , A61K2039/54 , A61K2039/575 , A61K2039/70 , C12N7/00 , C12N2770/24121 , C12N2770/24134 , C12N2770/24161 , C12N2770/24162 , C12N2770/24171 , C12Q1/701 , C12Q2600/156 , G01N2333/18 , G01N2500/10 , Y02A50/386
摘要: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
-
公开(公告)号:US20180008689A1
公开(公告)日:2018-01-11
申请号:US15545481
申请日:2016-01-28
申请人: INSTITUT PASTEUR
CPC分类号: A61K39/12 , A61K2039/5254 , C12N7/00 , C12N2760/00062 , C12N2760/16134 , C12N2760/16162 , C12N2770/00062 , C12N2770/24134 , C12N2770/24162 , C12N2770/32334 , C12N2770/32362 , Y02A50/383 , Y02A50/388
摘要: The application generally relates to the attenuation of a RNA virus or of a clone thereof and involves the alteration of sequence space, more particularly the reduction, of mutational robustness of said RNA virus or clone. The means of the application are more particularly dedicated to the attenuation of an infectious RNA virus or clone, for the production of immunogenic composition or vaccine. More particularly, the means of the application involve the replacement of codon(s) by different codon(s), which is(are) selected to differ by only one nucleotide from a codon STOP, more particularly by different but synonymous codon(s), which is(are) selected to differ by only one nucleotide from a codon STOP.
-
公开(公告)号:US08889148B2
公开(公告)日:2014-11-18
申请号:US13173895
申请日:2011-06-30
申请人: Dennis T. Brown , Raquel Hernandez
发明人: Dennis T. Brown , Raquel Hernandez
IPC分类号: A61K39/12 , C07K14/005 , C07H21/04 , A61K39/145 , C12N7/00 , C12N15/86 , A61K39/00
CPC分类号: C12N7/00 , A61K39/12 , A61K2039/525 , A61K2039/5254 , C07K14/005 , C12N15/86 , C12N2770/24122 , C12N2770/24134 , C12N2770/24145 , C12N2770/24162 , C12N2770/24171 , Y02A50/386 , Y02A50/388 , Y02A50/39 , Y02A50/394 , Y02A50/396
摘要: Methods and compositions concerning mutant flaviviruses with host-range phenotypes are provided. Nucleotide sequences that encode mutant flavivirus proteins are also provided. In certain aspects, viruses comprising these sequences display reduced replication in mammalian cells. In further aspects of the invention, flavivirus vaccine compositions and methods for vaccination against flavivirus infection are provided.
摘要翻译: 提供了关于具有宿主范围表型的突变型黄病毒的方法和组合物。 还提供了编码突变黄病毒蛋白的核苷酸序列。 在某些方面,包含这些序列的病毒在哺乳动物细胞中显示出降低的复制。 在本发明的另外的方面,提供黄病毒疫苗组合物和用于接种黄病毒感染的方法。
-
公开(公告)号:US08715689B2
公开(公告)日:2014-05-06
申请号:US12990322
申请日:2009-04-27
IPC分类号: A61K39/295 , A61K48/00
CPC分类号: C12N7/00 , A61K39/12 , A61K2039/5256 , A61K2039/53 , A61K2039/70 , C07K14/005 , C12N2770/24122 , C12N2770/24134 , C12N2770/24162 , Y02A50/386 , Y02A50/394
摘要: The disclosure provides chimeric West Nile/Dengue viruses comprising non-coding regions, non-structural proteins, and a C protein from a West Nile virus and prM and E proteins from a Dengue virus. Also disclosed are methods of using the chimeric viruses in diagnosis of Dengue viral infection, assessment of candidate Dengue virus vaccine efficacy, and production of Dengue prM and E proteins.
摘要翻译: 本公开提供了包含非编码区,非结构蛋白和来自西尼罗河病毒的C蛋白和来自登革病毒的prM和E蛋白的嵌合西尼罗河/登革病毒。 还公开了使用嵌合病毒诊断登革热病毒感染,评估候选登革热病毒疫苗功效以及登革热prM和E蛋白的产生的方法。
-
公开(公告)号:US20130243812A1
公开(公告)日:2013-09-19
申请号:US13633436
申请日:2012-10-02
IPC分类号: C12N15/86 , A61K39/295
CPC分类号: C12N15/86 , A61K39/12 , A61K39/155 , A61K39/205 , A61K39/295 , A61K2039/5254 , A61K2039/5256 , A61K2039/70 , C07K14/005 , C12N7/00 , C12N2760/18534 , C12N2760/20134 , C12N2770/24121 , C12N2770/24122 , C12N2770/24134 , C12N2770/24143 , C12N2770/24162 , Y02A50/386 , Y02A50/388 , Y02A50/39 , Y02A50/394 , Y02A50/396 , Y02A50/401 , Y02A50/412
摘要: This invention provides replication-defective flavivirus vaccines and vaccine vectors, and corresponding compositions and methods.
摘要翻译: 本发明提供了复制缺陷型黄病毒疫苗和疫苗载体,以及相应的组合物和方法。
-
-
-
-
-
-
-
-
-